Inclusion Criteria

Inclusion criteria:

- Signed written informed consent

- Male and female patients > or = 18 years of age with a solid tumor(s) refractory to
standard curative therapy or for which no curative therapy exists

- Clinically or radiologically documented measurable disease.

- Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in
archived or fresh tumor tissue

- Adequate performance status and organ function, as evidenced by hematological and
biochemical blood testing and electrocardiogram (ECG)

Exclusion criteria:

- Receipt of ADH-1 prior to this clinical study

- Chemotherapy, radiotherapy, or any other investigational drug within 30 days before
study entry

- History of primary brain tumors or brain metastases

- History of spinal cord compression or tumors that have shown any evidence of active
bleeding within 30 days before study entry.

- Stroke, major surgery, or other major tissue injury within 30 days before study entry

- History of congestive heart failure, myocardial infarction, angina, life threatening
arrhythmias, significant electrocardiogram (ECG) abnormalities, or known
hypercoagulable states